Carl Akin
Cardiovascular Disease · Independence, MONPI 1871598052
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 97.6% of the total across 195 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 24 manufacturers, the largest accounting for just 21.8% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $1,162 and has fallen 97.5% since, to $29 in 2023.
Across 195 payments — averaging $15.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$654
- Amgen$577
- Sanofi-aventis U.S. LLC$266
- Amarin Pharma, Inc.$189
- Boehringer Ingelheim$184
- E.r. Squibb & Sons, L.L.C.$173
- plus $954 from 18 others
What the payments were for
- Consulting fees$201%
- Food & beverage$2,92898%
- Education$502%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 38 | $654 |
| Amgen | 42 | $577 |
| Sanofi-aventis U.S. LLC | 20 | $266 |
| Amarin Pharma, Inc. | 11 | $189 |
| Boehringer Ingelheim | 12 | $184 |
| E.r. Squibb & Sons, L.L.C. | 13 | $173 |
| Pfizer | 9 | $134 |
| Boston Scientific | 7 | $132 |
| Novartis | 9 | $128 |
| AstraZeneca | 7 | $111 |
| Regeneron Healthcare Solutions, Inc. | 5 | $79 |
| Actelion Pharmaceuticals US, Inc. | 3 | $55 |
| Bayer | 2 | $41 |
| Nuwellis, Inc. | 1 | $32 |
| Biotronik Inc. | 2 | $32 |
| Lundbeck LLC | 2 | $31 |
| Philips North America LLC | 2 | $29 |
| Merck | 2 | $28 |
| Esperion Therapeutics, Inc. | 2 | $28 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 2 | $26 |
| Aegerion Pharmaceuticals, Inc. | 1 | $20 |
| Z-medica, LLC | 1 | $20 |
| Amryt Pharma Holdings Ltd | 1 | $17 |
| Kowa Pharmaceuticals America, Inc. | 1 | $11 |
How this compares
$2,998 in reported general payments places this provider in the 60th percentile of 391 cardiovascular disease providers in Missouri.
Other cardiovascular disease in Independence
- Stephen DicksonIndependence$98K
- Thao DuongIndependence$27K
- Mikhail KosiborodKansas City$1.1M
- Georges ChahoudSaint Louis$937K
- William BowenSaint Louis$726K
- Daniel KellySaint Louis$582K
- John SpertusKansas City$360K
- James FairlambColumbia$342K
- James EllisonChesterfield$267K
- Osler Jay GuzonSaint Louis$211K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.